Mergers & Acquisitions ·
Mentari Therapeutics completes merger with InMed Pharmaceuticals and raises $490 million
INMInMed Pharmaceuticals Inc.
Mentari Therapeutics, Inc. (formerly InMed Pharmaceuticals) completed its previously disclosed merger with InMed Pharmaceuticals on November 9, 2026. The combined company operates under the name Mentari Therapeutics, Inc., and shares began trading on the Nasdaq Capital Market under the ticker symbol MTRI. Immediately prior to closing, Mentari raised approximately $490 million in gross proceeds through private placement financings led by Fairmount, including the conversion of $50.0 million in convertible notes plus accrued interest. Todd Shegog was appointed to the Board of Directors as Chair of the Audit Committee. The company is a clinical-stage biotechnology firm developing next-generation biologics for migraine prevention.